Carfilzomib

Leukemia

Stanford UniversitySmall moleculePhase 1Dormant

CC

44/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
ASPARAGINASE Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 3	BB
THIOGUANINE ANHYDROUS Incyte Corporation	Phase 3	BB
Idarubicine Affiliated Hospital of Nantong University	Phase 3	BB
Daunorubicin Richard Stone, MD	Phase 3	BB

View all 50 →

Same molecule, other indications

Carfilzomib is also rated in:

plasma cell myelomaDormant

BB

Indicative ·

67 / 100

MRDDormant

BB

Indicative ·

64 / 100

Stage III Adult Diffuse Large Cell LymphomaDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.